FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (5)

• Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication Psychiatric Times · 2d ago
• Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older mykxlg.com · 2d ago
• FDA Rules Today on First New-Class ADHD Drug for Kids and Adults in Decades Medical Daily · 2d ago
• Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 2d ago
• FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 2d ago

Related trends